Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma.
Administration, Metronomic
Administration, Oral
Adult
Antimetabolites, Antineoplastic
/ administration & dosage
Chemoradiotherapy
Disease-Free Survival
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Nasopharyngeal Carcinoma
/ mortality
Nasopharyngeal Neoplasms
/ mortality
Neoplasm Staging
Retrospective Studies
Survival Rate
Tegafur
/ administration & dosage
Uracil
/ administration & dosage
UFUR
cancer
metronomic
nasopharyngeal
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
18
08
2018
revised:
05
06
2019
accepted:
22
07
2019
pubmed:
23
8
2019
medline:
21
11
2020
entrez:
23
8
2019
Statut:
ppublish
Résumé
The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC). Data were retrospectively analyzed from a database of patients with non-distant metastatic TNM stage IV NPC, composed of those who underwent CCRT for CR from January 2010 through December 2017. Thirty-three patients were treated with CCRT (the non-UFUR group), and the other 37 patients were treated with the same regimen, followed by additional oral UFUR (the UFUR group). Importantly, the 5-year OS rates were 91.89% in the UFUR group and 57.58% in the non-UFUR group (P = .004). Adding UFUR to CCRT was found to significantly improve the DFS and OS rates of patients with non-distant metastatic TNM stage IV NPC. The authors cautiously suggest UFUR as possible maintenance therapy following CCRT.
Sections du résumé
BACKGROUND
The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC).
METHODS
Data were retrospectively analyzed from a database of patients with non-distant metastatic TNM stage IV NPC, composed of those who underwent CCRT for CR from January 2010 through December 2017.
RESULTS
Thirty-three patients were treated with CCRT (the non-UFUR group), and the other 37 patients were treated with the same regimen, followed by additional oral UFUR (the UFUR group). Importantly, the 5-year OS rates were 91.89% in the UFUR group and 57.58% in the non-UFUR group (P = .004).
CONCLUSIONS
Adding UFUR to CCRT was found to significantly improve the DFS and OS rates of patients with non-distant metastatic TNM stage IV NPC. The authors cautiously suggest UFUR as possible maintenance therapy following CCRT.
Substances chimiques
Antimetabolites, Antineoplastic
0
Tegafur
1548R74NSZ
Uracil
56HH86ZVCT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3775-3782Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765-1777.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
Nasopharyngeal cancer: statistics. Approved by the Cancer.Net Editorial Board, July 2017.
Huang WY, Lin CL, Lin CY, et al. Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13 407 patients in Taiwan. Clin Otolaryngol. 2015 Aug;40(4):327-334.
Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61:1107-1116.
Vives M, Ginesta MM, Gracova K, et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer. 2013;133:2464-2472.
Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28:2051-2057.
Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101:1986-1994.
Watanabe T, Sano M, Takashima S, et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for breast Cancer 01 trial. J Clin Oncol. 2009;27:1368-1374.
Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713-1721.
Hsu CH, Shen YC, Lin ZZ, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010;53:126-131.
Shao YY, Lin ZZ, Hsu C, et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology. 2012;82:59-66.
Lin PC, Chen WS, Chao TC, Yang SH, Tiu CM, Liu JH. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007;60:351-356.
Ogata Y, Sasatomi T, Mori S, et al. Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. Anticancer Res. 2007;27:2605-2611.
Fontana A, Galli L, Fioravanti A, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15:4954-4962.
Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177:2136-2140.
Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010;11:350-357.
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia. J Clin Oncol. 2008;26:76-82.
AL-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer. 2010;10:558.
Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys May 1, 2014;89(1):21-9.
Liu YC, Wang WY, Twu CW, et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. Oral Oncol. 2017 Jan;64:15-21.
Lin JC1, Liang WM, Jan JS, et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma-is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004 Sep 1;60(1):156-64.
Lo YM, Chan ATC, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis circulating Epstein-Barr virus DNA. Cancer Res. 2000;60:6878-6881.
Lin JC, Wang WY, Chen KY, et al. Quantification plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461-2470.
Wang WY, Twu CW, Chen HH, et al. Plasma Epstein-Barr virus DNA clearance rate as a novel prognostic marker for metastatic/ recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16:1016-1024.
Lo YMD, Leung SF, Chan LYS, et al. Plasma cell- Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann NY Acad Sci. 2000;906:99-101.
Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358:100-106.
Klement GL, Kamen BA. Nontoxic, fiscally responsible, future of oncology: could it be beginning in the third world? J Pediatr Hematol Oncol. 2011;33:1-3.
Hanahan D, Burgers G, Bergsland E. Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573-581.